Graft vs Host Disease

• 

  Subject Areas on Research

  • A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease. 
  • A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. 
  • A clinical review: cutaneous manifestations of acute and chronic graft-versus-host disease following bone marrow transplantation. 
  • A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. 
  • A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. 
  • A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. 
  • A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases. 
  • A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. 
  • A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. 
  • A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. 
  • A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. 
  • A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia. 
  • A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. 
  • A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome. 
  • A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. 
  • A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants. 
  • Aberrant B-cell homeostasis in chronic GVHD. 
  • Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Acute and chronic graft-versus-host disease in man. 
  • Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimens. 
  • Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. 
  • Acute graft-versus-host disease: are we close to bringing the bench to the bedside? 
  • Acute graft-vs-host disease: pathobiology and management. 
  • Acute myelogenous leukemia associated with Ollier disease. 
  • Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease. 
  • Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. 
  • Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning. 
  • Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. 
  • Advances in the understanding and treatment of human severe combined immunodeficiency. 
  • Alemtuzumab for the prevention and treatment of graft-versus-host disease. 
  • Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study. 
  • Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. 
  • Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. 
  • Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. 
  • Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia. 
  • Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. 
  • Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. 
  • Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. 
  • Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. 
  • Allogeneic marrow transplantation. 
  • Allogeneic memory T cell response. 
  • Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. 
  • Allogeneic small bowel transplantation with cyclosporine and donor whole-body irradiation. 
  • Allogeneic splenocyte transfer and lipopolysaccharide inhalations induce differential T cell expansion and lung injury: a novel model of pulmonary graft-versus-host disease. 
  • Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. 
  • Allogeneic stem cell transplantation with omidubicel in sickle cell disease. 
  • Allospecific CD4(+) effector memory T cells do not induce graft-versus-host disease in mice. 
  • Alterations in natural anticoagulant levels during allogeneic bone marrow transplantation: a prospective study in 27 patients. 
  • Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. 
  • Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. 
  • Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. 
  • An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. 
  • Anaerobic Antibiotics and the Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. 
  • Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. 
  • Antibodies are back for thymic attack in cGVHD. 
  • Antigen-specific T-lymphocyte function after cord blood transplantation. 
  • Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. 
  • Apoptotic Donor Cells in Transplantation. 
  • Appearance of multiple benign paraproteins during early engraftment of soy lectin T cell-depleted haploidentical bone marrow cells in severe combined immunodeficiency. 
  • Are there effective new strategies for the treatment of acute and chronic GvHD? 
  • Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. 
  • Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. 
  • Autologous serum eye drops for severe dry eye syndrome in a patient with chronic graft-versus-host disease: a case report. 
  • B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. 
  • B cells in chronic graft-versus-host disease. 
  • B cells in chronic graft-versus-host disease. 
  • B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. 
  • B-cell targeting in chronic graft-versus-host disease. 
  • BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation. 
  • BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT. 
  • Biomarkers in chronic graft-versus-host disease: quo vadis? 
  • Blazing a new TRAIL in hematopoietic cell transplantation. 
  • Bone density loss during treatment of chronic GVHD. 
  • Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development. 
  • Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. 
  • Bone marrow transplantation for sickle cell disease. 
  • Bone marrow transplantation for sickle cell disease. The United States experience. 
  • Bone marrow transplantation for thalassemia. The USA experience. 
  • Bone marrow transplantation in patients aged 45 years and older. 
  • Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. 
  • Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD. 
  • Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial. 
  • Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. 
  • Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. 
  • Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. 
  • CT-039 Health-Related Quality of Life Following Allogeneic Hematopoietic Stem Cell Transplantation With Omidubicel Versus Standard Umbilical Cord Blood. 
  • CT-314 Multicenter Long-Term Follow Up of Allogeneic Hematopoietic Stem Cell Transplantation With Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials. 
  • Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation. 
  • Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. 
  • Changing trends in marrow transplantation for aplastic anemia. 
  • Children Receiving Hematopoietic Stem Cell Transplantation are at Increased Risk of Onychocryptosis Requiring Surgical Management. 
  • Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. 
  • Chronic GVHD of the CNS. 
  • Chronic Graft-versus-Host Disease: A Long Road Ahead. 
  • Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. 
  • Chronic cutaneous graft-versus-host disease in man. 
  • Chronic graft-versus-host disease and other late complications of bone marrow transplantation. 
  • Chronic graft-versus-host disease, obliterative bronchiolitis, and graft-versus-leukemia effect: case histories. 
  • Chronic graft-versus-host disease. 
  • Chronic graft-versus-host disease. 
  • Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. 
  • Cirrhosis of the liver in long-term marrow transplant survivors. 
  • Clinical Outcomes of Older Kidney Transplant Recipients. 
  • Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. 
  • Clinical applications for biomarkers of acute and chronic graft-versus-host disease. 
  • Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. 
  • Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI. 
  • Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. 
  • Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions. 
  • Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. 
  • Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. 
  • Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. 
  • Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. 
  • Complete DiGeorge syndrome: persistence of profound immunodeficiency. 
  • Complications of allogeneic bone marrow transplantation. 
  • Composite tissue allotransplantation: current challenges. 
  • Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. 
  • Consensus diagnostic histopathological criteria for acute gastrointestinal graft versus host disease improve interobserver reproducibility. 
  • Cord blood stem cells. 
  • Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. 
  • Coronary artery occlusion secondary to graft versus host disease after bone marrow transplant in a 21-year-old. 
  • Correction of chronic granulomatous disease after second unrelated-donor umbilical cord blood transplantation. 
  • Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. 
  • Critical assessment of automated flow cytometry data analysis techniques. 
  • Current status of bone marrow transplantation. 
  • Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. 
  • Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. 
  • Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. 
  • Cyclosporine treatment of chronic graft-versus-host disease following allogeneic bone marrow transplantation. 
  • Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. 
  • Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. 
  • Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. 
  • Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy. 
  • Depletion of host reactive T cells by photodynamic cell purging and prevention of graft versus host disease. 
  • Dermatomal sclerodermoid graft-vs-host disease following varicella-zoster virus infection. 
  • Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. 
  • Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease. 
  • Direct ultrastructural evidence of target-directed polarization by cytotoxic lymphocytes in lesions of human graft-vs-host disease. 
  • Disordered salivary immunoglobulin secretion and sodium transport in human chronic graft-versus-host disease. 
  • Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. 
  • Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers. 
  • Donor Allospecific CD44high Central Memory T Cells Have Decreased Ability to Mediate Graft-vs.-Host Disease. 
  • Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. 
  • Donor immune reconstitution after liver-small bowel transplantation for multiple intestinal atresia with immunodeficiency. 
  • Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. 
  • Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. 
  • Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience. 
  • Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. 
  • Durable engraftment and correction of hematological abnormalities in children with congenital amegakaryocytic thrombocytopenia following myeloablative umbilical cord blood transplantation. 
  • Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. 
  • Early and late interstitial pneumonia following human bone marrow transplantation. 
  • Economic and clinical burden associated with respiratory viral infections after allogeneic hematopoietic cell transplant in the United States. 
  • Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. 
  • Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. 
  • Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. 
  • Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. 
  • Effects of Immunosuppressive Medications on Mitochondrial Function. 
  • Effects of treatment regimens on post marrow transplant relapse. 
  • Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. 
  • Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. 
  • Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation. 
  • Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. 
  • Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. 
  • Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. 
  • Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia. 
  • Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. 
  • Ex vivo spermine dialdehyde treatment prevents lethal GVHD in a murine bone marrow transplantation model. 
  • Exuberant granulation tissue associated with chronic graft-versus-host disease after transplantation of peripheral blood progenitor cells. 
  • FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. 
  • Factors predicting chronic graft-versus-host disease and survival after marrow transplantation for aplastic anemia. 
  • Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors. 
  • Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation. 
  • Finally, a Successful Randomized Trial for GVHD. 
  • Flow cytometric detection of lymphocyte proliferation in eyes with immunogenic inflammation. 
  • Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. 
  • Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. 
  • Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. 
  • Further examination of BAFF SNPs in cGVHD. 
  • Gastric graft-versus-host disease: a blinded histologic study. 
  • Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. 
  • Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans. 
  • Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. 
  • Graft vascular disease after cardiac transplantation and its relationship to mean acute rejection score. 
  • Graft versus host disease following allogeneic bone marrow transplantation. 
  • Graft versus host disease-related secretory immunoglobulin A deficiency in bone marrow transplant recipients. Findings in labial saliva. 
  • Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. 
  • Graft-v-host disease is associated with autoimmune-like thrombocytopenia. 
  • Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. 
  • Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. 
  • Graft-versus-host disease prevention by rapamycin: cellular mechanisms. 
  • Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. 
  • Graft-versus-host disease: allo- and autoimmunity after bone marrow transplantation. 
  • Graft-versus-host disease: the viewpoint from the donor T cell. 
  • Graft-versus-leukemia in man: relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. 
  • Graft-versus-leukemia in the rat--the antileukemic efficacy of syngeneic and allogeneic graft-versus-host disease. 
  • Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. 
  • Growth and development following marrow transplantation for leukemia. 
  • Growth hormone accelerates immune recovery following allogeneic T-cell-depleted bone marrow transplantation in mice. 
  • Growth patterns and gastrointestinal symptoms in pediatric patients after hematopoietic stem cell transplantation. 
  • Guidelines for Pediatric Unrelated Cord Blood Transplantation-Unique Considerations. 
  • Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation. 
  • HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group. 
  • HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh. 
  • Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. 
  • Haploidentical hematopoietic cell transplantation. 
  • Hedgehog blockade in steroid-refractory sclerotic chronic graft-versus-host disease. 
  • Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. 
  • Hematopoietic Stem Cell Transplantation for CD40 Ligand Deficiency: Single Institution Experience. 
  • Hematopoietic cell transplantation for Chediak-Higashi syndrome. 
  • Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. 
  • Hematopoietic stem cell transplantation for complete IFN-gamma receptor 1 deficiency: a multi-institutional survey. 
  • Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. 
  • Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. 
  • Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. 
  • Hematopoietic stem-cell transplantation. 
  • Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. 
  • Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. 
  • Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis. 
  • High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. 
  • High-dose intravenous immunoglobulin as adjuvant treatment for grade IV acute cutaneous graft-versus-host disease. 
  • How I treat refractory chronic graft-versus-host disease. 
  • Human Mesenchymal Stem Cell-Educated Macrophages Are a Distinct High IL-6-Producing Subset that Confer Protection in Graft-versus-Host-Disease and Radiation Injury Models. 
  • Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. 
  • I have a gut feeling…. 
  • IL-17A Contributes to Lung Fibrosis in a Model of Chronic Pulmonary Graft-versus-host Disease. 
  • Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. 
  • Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. 
  • Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. 
  • Immunoglobulin therapy in bone marrow transplantation. 
  • Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. 
  • Immunomodulation in stem-cell transplantation. 
  • Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. 
  • Immunomodulatory peptides with high binding affinity for class II MHC molecules for the prevention of graft-versus-host disease. 
  • Impact of different forms of recipient antigen and different routes of antigen administration in donor pretreatment for preventing graft-versus-host disease in rat small bowel transplantation. 
  • Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD. 
  • In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. 
  • Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. 
  • Incompatible bone-marrow transplantation in lymphopenic immunologic deficiency. Circumvention of fatal graft-versus-host disease by immunologic enhancement. 
  • Increased BCR responsiveness in B cells from patients with chronic GVHD. 
  • Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. 
  • Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. 
  • Infections diagnosed in the first year after pediatric stem cell transplantation. 
  • Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. 
  • Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. 
  • Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation. 
  • Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. 
  • Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. 
  • Innate immune activation by the viral PAMP poly I:C potentiates pulmonary graft-versus-host disease after allogeneic hematopoietic cell transplant. 
  • Innate immune activation potentiates alloimmune lung disease independent of chemokine (C-X-C motif) receptor 3. 
  • International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part I). 
  • Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease. 
  • Intestinal Acute Graft-versus-Host Disease: A Bug Highway to the Bloodstream. 
  • Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. 
  • Intestinal and hepatic complications of human bone marrow transplantation. Part I. 
  • Intestinal and hepatic complications of human bone marrow transplantation. Part II. 
  • Intravenous IgG to prevent graft-versus-host disease after bone marrow transplantation. 
  • Intravenous immune globulin prophylaxis in recipients of a marrow transplant. 
  • Introduction to a symposium on sickle cell anemia: current results of comprehensive care and the evolving role of bone marrow transplantation. 
  • L-selectin is dispensable for T regulatory cell function postallogeneic bone marrow transplantation. 
  • Lactose drives Enterococcus expansion to promote graft-versus-host disease. 
  • Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults. 
  • Late complications after marrow transplantation. 
  • Late complications of allogeneic and autologous marrow transplantation. 
  • Location, location, location: regional immune mechanisms critically influence rejection. 
  • Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. 
  • Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. 
  • Long-term complications of bone marrow transplantation. 
  • Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. 
  • Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. 
  • Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. 
  • Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. 
  • Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. 
  • Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia. 
  • Long-term outcome after marrow transplantation for severe aplastic anemia. 
  • Long-term outcome of non-ablative booster BMT in patients with SCID. 
  • Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb. 
  • Long-term survival and cure after marrow transplantation for congenital hypoplastic anaemia (Diamond-Blackfan syndrome). 
  • Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. 
  • Longitudinal analysis of T-cell receptor variable beta chain repertoire in patients with acute graft-versus-host disease after allogeneic stem cell transplantation. 
  • Longterm followup and quality of life after hematopoietic stem cell transplantation. 
  • Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. 
  • MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT. 
  • Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. 
  • Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. 
  • Marrow transplant experience for children with severe aplastic anemia. 
  • Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse, and graft-versus-host disease. 
  • Marrow transplantation for Fanconi anemia with or without leukemic transformation: an update of the Seattle experience. 
  • Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. 
  • Marrow transplantation for aplastic anemia. 
  • Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. 
  • Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. 
  • Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. 
  • Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. 
  • Marrow transplantation for severe aplastic anemia and thalassemia major. 
  • Marrow transplantation for severe aplastic anemia. Long-term outcome in fifty "untransfused" patients. 
  • Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. 
  • Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. 
  • Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. 
  • Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. 
  • Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model. 
  • Memory T cells. 
  • Memory T cells: A helpful guard for allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease. 
  • Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. 
  • Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? 
  • MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. 
  • Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months. 
  • Minors come of age: Minor histocompatibility antigens and graft-versus-host disease. 
  • Mixed leukocyte culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukemia. 
  • Modeling Chronic Graft-versus-Host Disease in MHC-Matched Mouse Strains: Genetics, Graft Composition, and Tissue Targets. 
  • Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD. 
  • Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. 
  • Mouse Adenovirus Type 1 Persistence Exacerbates Inflammation Induced by Allogeneic Bone Marrow Transplantation. 
  • Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. 
  • Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. 
  • Myasthenia gravis after allogeneic bone marrow transplantation: relationship to chronic graft-versus-host disease. 
  • Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. 
  • Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. 
  • Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease. 
  • Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. 
  • NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. 
  • National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. 
  • National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. 
  • National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. 
  • National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. 
  • National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. 
  • Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy. 
  • New developments in allotransplant immunology. 
  • New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. 
  • Non-pharmacologic approaches to graft-versus-host prevention. 
  • Noninfectious transfusion-associated adverse events and their mitigation strategies. 
  • Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. 
  • Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice. 
  • Novel Scoring Criteria for the Evaluation of Ocular Graft-versus-Host Disease in a Preclinical Allogeneic Hematopoietic Stem Cell Transplantation Animal Model. 
  • Novel mechanism of rapamycin in GVHD: increase in interstitial regulatory T cells. 
  • Novel role for surfactant protein A in gastrointestinal graft-versus-host disease. 
  • Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. 
  • Ocular manifestations of graft-v-host disease. 
  • Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. 
  • One-unit versus two-unit cord-blood transplantation for hematologic cancers. 
  • Oral beclomethasone therapy for recurrent small bowel allograft rejection and intestinal graft-versus-host disease. 
  • Oral manifestations of chronic graft-v-host disease. 
  • Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. 
  • Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. 
  • Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. 
  • Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis. 
  • Outcomes among 562 recipients of placental-blood transplants from unrelated donors. 
  • Outcomes of 122 diverse adult and pediatric cord blood transplant recipients from a large cord blood bank. 
  • Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. 
  • Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection. 
  • Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning. 
  • Outcomes of pediatric patients with therapy-related myeloid neoplasms. 
  • Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. 
  • Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy. 
  • PG27, an extract of Tripterygium wilfordii hook f, induces antigen-specific tolerance in bone marrow transplantation in mice. 
  • Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial. 
  • Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. 
  • Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. 
  • Pathophysiologic mechanisms of acute graft-vs.-host disease. 
  • Pathophysiology and treatment of graft-versus-host disease. 
  • Perspective: research highlights at the Duke University center for AIDS research. Immunoreconstitution in HIV infection: the role of the thymus. 
  • Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. 
  • Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation. 
  • Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. 
  • Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. 
  • Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. 
  • Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. 
  • Photoinactivation of lymphohemopoietic cells: studies in transfusion medicine and bone marrow transplantation. 
  • Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. 
  • Plasma CXCL9 and CXCL10 at allograft injury predict chronic lung allograft dysfunction. 
  • Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. 
  • Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease. 
  • Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. 
  • Polymyositis as a manifestation of chronic graft-versus-host disease. 
  • Polymyositis as a manifestation of chronic graft-versus-host disease. 
  • Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. 
  • Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. 
  • Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes. 
  • Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. 
  • Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality. 
  • Prebiotic galactooligosaccharides interact with mouse gut microbiota to attenuate acute graft-versus-host disease. 
  • Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. 
  • Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes. 
  • Prevalence of nutrition-related problems among long-term survivors of allogeneic marrow transplantation. 
  • Prevention and treatment of graft-versus-host disease. 
  • Prevention of GVHD without losing GVL effect: windows of opportunity. 
  • Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion. 
  • Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. 
  • Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. 
  • Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. 
  • Progress in graft-versus-host disease. 
  • Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. 
  • Prophylaxis and treatment of acute graft-versus-host disease. 
  • Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. 
  • Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants. 
  • Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. 
  • Protective role of T-bet and Th1 cytokines in pulmonary graft-versus-host disease and peribronchiolar fibrosis. 
  • Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. 
  • Quantifying Skin Stiffness in Graft-Versus-Host Disease, Morphea, and Systemic Sclerosis Using Acoustic Radiation Force Impulse Imaging and Shear Wave Elastography. 
  • Radiographic features of esophageal involvement in chronic graft-vs.-host disease. 
  • Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. 
  • Rapamycin suppression of host-versus-graft and graft-versus-host disease in MHC-mismatched rats. 
  • Rapidly progressive air-flow obstruction in marrow transplant recipients. Possible association between obliterative bronchiolitis and chronic graft-versus-host disease. 
  • Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. 
  • Recognition, incidence, and management of oral graft-versus-host disease. 
  • Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. 
  • Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. 
  • Recovery of in vivo cellular immunity after human marrow grafting. Influence of time postgrafting and acute graft-versus-host disease. 
  • Recruitment of Donor T Cells to the Eyes During Ocular GVHD in Recipients of MHC-Matched Allogeneic Hematopoietic Stem Cell Transplants. 
  • Recurrent acute inflammatory demyelinating polyradiculitis after allogeneic bone marrow transplantation. 
  • Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. 
  • Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002). 
  • Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation. 
  • Regulating regulatory T cells. 
  • Rejection of canine cardiac allografts. 
  • Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. 
  • Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors. 
  • Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia. 
  • Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. 
  • Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. 
  • Reversible leukoencephalopathy associated with graft-versus-host disease: MR findings. 
  • Review of chronic graft-versus-host disease in children after allogeneic stem cell transplantation: nursing perspective. 
  • Risk factors for acute GVHD and survival after hematopoietic cell transplantation. 
  • Risk factors for acute graft-versus-host disease associated with cyclosporine and methotrexate prophylaxis. 
  • Risk factors for airflow obstruction in recipients of bone marrow transplants. 
  • Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. 
  • Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. 
  • Role of C-C motif ligand 2 and C-C motif receptor 2 in murine pulmonary graft-versus-host disease after lipopolysaccharide inhalations. 
  • Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. 
  • Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease. 
  • SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies. 
  • SYK inhibitor entospletinib prevents ocular and skin GVHD in mice. 
  • Science of composite tissue allotransplantation. 
  • Second marrow infusion for poor graft function after allogeneic marrow transplantation. 
  • Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation. 
  • Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. 
  • Secondary failure of platelet recovery after hematopoietic stem cell transplantation. 
  • Secreted osteopontin from CD4+ T cells limits acute graft-versus-host disease. 
  • Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting. 
  • Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. 
  • Severe combined immunodeficiency with natural killer-cell predominance: abrogation of graft-versus-host disease and immunologic reconstitution with HLA-identical bone marrow cells. 
  • Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors. 
  • Sibling umbilical cord blood infusion is safe in young children with cerebral palsy. 
  • Single-cell analysis of immune cell transcriptome during HIV-1 infection and therapy. 
  • Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. 
  • Spontaneous factor VIII inhibitor occurring in association with chronic graft-versus-host disease. 
  • Stem-cell transplantation for sickle cell disease. 
  • Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. 
  • Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children. 
  • Supportive care of the marrow transplant recipient: the Seattle Experience. 
  • Survey of Irradiation Practice for the Prevention of Transfusion-Associated Graft-versus-Host Disease. 
  • Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. 
  • Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation. 
  • T-Cell recovery in adults and children following umbilical cord blood transplantation. 
  • TNF, LTA and TGFB1 genotype distributions among acute graft-vs-host disease subsets after HLA-matched unrelated hematopoietic stem cell transplantation: a pilot study. 
  • Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. 
  • Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. 
  • Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect. 
  • Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. 
  • Thalidomide as salvage therapy for chronic graft-versus-host disease. 
  • The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. 
  • The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review. 
  • The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. 
  • The Knife's Edge of Tolerance: Inducing Stable Multilineage Mixed Chimerism but With a Significant Risk of CMV Reactivation and Disease in Rhesus Macaques. 
  • The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success. 
  • The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation. 
  • The effect of natural killer cell killer Ig-like receptor alloreactivity on the outcome of bone marrow stem cell transplantation for severe combined immunodeficiency (SCID). 
  • The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia. 
  • The management of chronic graft-versus-host disease. 
  • The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. 
  • The pathophysiology and treatment of graft-versus-host disease. 
  • The role of adenotonsillectomy in graft-versus-host disease. 
  • The role of oral beclometasone dipropionate in the treatment of gastrointestinal Graft-versus-Host Disease. 
  • The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. 
  • The use of umbilical cord blood in mismatched related and unrelated hemopoietic stem cell transplantation. 
  • Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. 
  • Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. 
  • To D or not to D: vitamin D in hematopoietic cell transplantation. 
  • Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. 
  • Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. 
  • Transfer of specific immunity in marrow recipients given HLA-mismatched, T cell-depleted, or HLA-identical marrow grafts. 
  • Transfusion effect on graft-versus-host disease and leukemic relapse in HLA-matched bone marrow transplantation. 
  • Transfusions shortly before HLA-matched marrow transplantation for leukemia are associated with a decrease in chronic graft-versus-host disease. 
  • Transplantation of the entire small bowel in inbred rats using cyclosporine. 
  • Transplantation outcomes for severe combined immunodeficiency, 2000-2009. 
  • Traumatic Brain Injury and Chronic Implications Beyond the Brain. 
  • Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. 
  • Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. 
  • Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. 
  • Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. 
  • Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. 
  • Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. 
  • Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. 
  • Treatment of marrow graft recipients with thymopentin. 
  • Treatment of non-Hodgkin's lymphoma with chemoradiotherapy and allogenic marrow transplantation. 
  • Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. 
  • Two Cases and a Review of Graft-Versus-Host Disease and the Role of Hepatitis C Treatment in Liver Transplant Patients. 
  • Two cases of transfusion-associated graft-vs-host disease after open heart surgery. 
  • Umbilical cord blood hematopoietic stem and repopulating cells in human clinical transplantation. 
  • Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. 
  • Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). 
  • Umbilical cord blood: a novel alternative source of hematopoietic stem cells for bone marrow transplantation. 
  • Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis. 
  • Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients. 
  • Unrelated donor marrow transplantation in children. 
  • Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. 
  • Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. 
  • Unrelated placental blood in marrow transplantation. 
  • Unrelated umbilical cord blood transplantation in adult patients. 
  • Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. 
  • Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease. 
  • Use of thymic grafts or thymic factors to augment immunologic recovery after bone marrow transplantation: brief report with 2 to 12 years' follow-up. 
  • Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. 
  • Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. 
  • Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy. 
  • Vitamin D has no impact on outcomes after HSCT in children-A retrospective study. 
  • What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? 
  • You cannot improve what you do not measure. 
  • microRNA-142 guards against autoimmunity by controlling Treg cell homeostasis and function. 
• 

  Keywords of People

  • Buckley, Rebecca Hatcher, Professor Emeritus of Pediatrics, Pediatrics, Allergy and Immunology
  • Cardones, Adela Rambi Guanco, Adjunct Associate Professor in the Department of Dermatology, Dermatology
  • Chen, Jun, Professor of Medicine, Duke Cancer Institute
  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • Halabi, Susan, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Lagoo, Anand Shreeram, Professor of Pathology, Pathology
  • Pastva, Amy Martha, Professor in Orthopaedic Surgery, Cell Biology
  • Tsalik, Ephraim, Adjunct Associate Professor in the Department of Medicine, Medicine, Infectious Diseases